Synthesis of a Key Building Block for HCV Protease Inhibitor Telaprevir

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: Synthesis of a Key Building Block for HCV Protease Inhibitor Telaprevir ; volume:11 ; number:01 ; year:2015 ; pages:0004-0004
Synfacts ; 11, Heft 01 (2015), 0004-0004

DOI: 10.1055/s-0034-1379645

URN: urn:nbn:de:101:1-2019011106224499996597

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 06.03.1201, 10:00 AM CET

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Other Objects (12)

Synthesis of HCV Protease Inhibitor MK-6325

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283

Lysosomotropic agents as HCV entry inhibitors

In silico investigation of HCV and RNA synthesis inhibitor antibiotic drugs as potential inhibitors of SARS‑CoV‑2 main protease (Mpro)

Hochschulschrift

Novel inhibitors for the protease Taspase1

Efficacy and safety of hepatitis C direct-acting protease inhibitors (DAA-PI ) in real life in HIV-HCV coinfected patients

Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis

Hesperidin identified from Citrus extracts potently inhibits HCV genotype 3a NS3 protease

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants

Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways

Synthesis of HCV Protease Inhibitor MK-6325

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283

Lysosomotropic agents as HCV entry inhibitors

In silico investigation of HCV and RNA synthesis inhibitor antibiotic drugs as potential inhibitors of SARS‑CoV‑2 main protease (Mpro)

Hochschulschrift

Novel inhibitors for the protease Taspase1

Efficacy and safety of hepatitis C direct-acting protease inhibitors (DAA-PI ) in real life in HIV-HCV coinfected patients

Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis

Hesperidin identified from Citrus extracts potently inhibits HCV genotype 3a NS3 protease

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants

Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways

Synthesis of HCV Protease Inhibitor MK-6325

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283

Lysosomotropic agents as HCV entry inhibitors

In silico investigation of HCV and RNA synthesis inhibitor antibiotic drugs as potential inhibitors of SARS‑CoV‑2 main protease (Mpro)

Hochschulschrift

Novel inhibitors for the protease Taspase1

Efficacy and safety of hepatitis C direct-acting protease inhibitors (DAA-PI ) in real life in HIV-HCV coinfected patients

Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis

Hesperidin identified from Citrus extracts potently inhibits HCV genotype 3a NS3 protease

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants

Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Synthesis of a Key Building Block for HCV Protease Inhibitor Telaprevir

Object Details

References and Relationships

Further information

Data provider

Other Objects (12)

Synthesis of HCV Protease Inhibitor MK-6325

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283

Lysosomotropic agents as HCV entry inhibitors

In silico investigation of HCV and RNA synthesis inhibitor antibiotic drugs as potential inhibitors of SARS‑CoV‑2 main protease (Mpro)

Novel inhibitors for the protease Taspase1

Efficacy and safety of hepatitis C direct-acting protease inhibitors (DAA-PI ) in real life in HIV-HCV coinfected patients

Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis

Hesperidin identified from Citrus extracts potently inhibits HCV genotype 3a NS3 protease

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants

Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways

Synthesis of HCV Protease Inhibitor MK-6325

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283

Lysosomotropic agents as HCV entry inhibitors

In silico investigation of HCV and RNA synthesis inhibitor antibiotic drugs as potential inhibitors of SARS‑CoV‑2 main protease (Mpro)

Novel inhibitors for the protease Taspase1

Efficacy and safety of hepatitis C direct-acting protease inhibitors (DAA-PI ) in real life in HIV-HCV coinfected patients

Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis

Hesperidin identified from Citrus extracts potently inhibits HCV genotype 3a NS3 protease

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants

Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways

Synthesis of HCV Protease Inhibitor MK-6325

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283

Lysosomotropic agents as HCV entry inhibitors

In silico investigation of HCV and RNA synthesis inhibitor antibiotic drugs as potential inhibitors of SARS‑CoV‑2 main protease (Mpro)

Novel inhibitors for the protease Taspase1

Efficacy and safety of hepatitis C direct-acting protease inhibitors (DAA-PI ) in real life in HIV-HCV coinfected patients

Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis

Hesperidin identified from Citrus extracts potently inhibits HCV genotype 3a NS3 protease

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants

Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways

Related objects

Reset password